Arteris, Inc. (NASDAQ:AIP – Free Report) VP Paul L. Alpern sold 1,748 shares of the business’s stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $7.02, for a total value of $12,270.96. Following the completion of the sale, the vice president now owns 44,230 shares of the company’s stock, valued at $310,494.60. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Arteris Price Performance
Shares of NASDAQ AIP opened at $6.90 on Friday. Arteris, Inc. has a twelve month low of $3.27 and a twelve month high of $9.07. The company has a current ratio of 1.85, a quick ratio of 1.85 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $244.05 million, a price-to-earnings ratio of -7.84 and a beta of 0.89. The business has a 50 day simple moving average of $6.12 and a 200-day simple moving average of $5.32.
Arteris (NASDAQ:AIP – Free Report) last issued its quarterly earnings results on Thursday, May 4th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. Arteris had a negative return on equity of 73.37% and a negative net margin of 57.12%. The business had revenue of $13.15 million during the quarter, compared to the consensus estimate of $11.86 million. As a group, equities research analysts expect that Arteris, Inc. will post -0.79 earnings per share for the current year.
Institutional Inflows and Outflows
About Arteris
Arteris, Inc provides semiconductor interconnect intellectual property (IP) and IP deployment solutions in the Americas, the Asia Pacific, Europe, and the Middle East. The company develops, licenses, and supports the on-chip interconnect fabric technology used in System-on-Chip (Soc) designs and Network-on-Chip (NoC) interconnect IP.
Further Reading
- Five stocks we like better than Arteris
- MarketBeat Week in Review – 7/3 – 7/7
- Pfizer Just Invested $25 million In This Biotech
- Cracks In The Labor Market? Not Yet, But They’re Coming
- Levi’s: Buy On The Dip Or Downtrend In Play?
- Who Wins And Who Loses With China’s Metal Restrictions
Receive News & Ratings for Arteris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arteris and related companies with MarketBeat.com's FREE daily email newsletter.